Message from the CEO of Abbvie Israel, Dr. Avi Matan:
Abbvie is a global biopharmaceutical company that develops medication for complex medical conditions, ranging from chronic illnesses to life-threatening diseases. As part of our commitment to patients in Israel, we are proud to support the meaningful and vital work of the organization Haverim L’Refuah over the years.
Placing the patient at the center is a deep commitment that guides us at Abbvie Israel—every day and in everything we do. Our support for Haverim L’Refuah brings this commitment to life.
We are grateful for the opportunity to support the activities of Haverim L’Refuah both in times of routine and during periods of emergency and crisis, by assisting patients who face difficulties in accessing treatment.
The support provided by Haverim L’Refuah to patients who have exhausted all standard treatment options and require compassionate-use therapies is invaluable. At Abbvie Israel, we share this commitment and make every possible effort to approve compassionate treatments for eligible patients.
We were deeply impressed by the resilience and dedication of Haverim L’Refuah, which were truly put to the test during the emergencies and crises our country experienced these past years, and by our shared, uncompromising commitment to ensuring that all patients receive their treatments on time.
I sincerely hope that we will continue to work together to promote the health of Israeli society and advance a future of medicine that is more innovative, high quality, and equitable.
